Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687128 · ClinicalTrials.gov registry record · NA
Exercise Dose-Response on Features of the Metabolic Syndrome
A NA study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
NCT00687128: Completed NA study, sponsored by Charles Drew University of Medicine and Science.
NCT00687128 is a NA study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00687128, a NA study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
Study Summary
This study investigates the degree of improvement in insulin resistance and features of the metabolic syndrome in non-diabetic overweight or obese subjects after training in a low-intensity, moderate-intensity or non-aerobic exercise program, as well as self-initiated exercise behavior after the assigned exercise program.
Interventions
- BEHAVIORAL Low-intensity treadmill exercise
- BEHAVIORAL Moderate-intensity treadmill exercise
- BEHAVIORAL Non-aerobic stretching exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2004-10 |
| Est. Completion | 2010-04 |
| Phase | NA |
What the finished NCT00687128 record still lists
NCT00687128 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Low-intensity treadmill exercise is the first listed.
NCT00687128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00687128 about?
NCT00687128 is a clinical study titled "Exercise Dose-Response on Features of the Metabolic Syndrome". This study investigates the degree of improvement in insulin resistance and features of the metabolic syndrome in non-diabetic overweight or obese subjects after training in a low-intensity, moderate-intensity or non-aerobic exercise program, as well as self-initiated exercise behavior after the ass...
What is the current status of trial NCT00687128?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2004-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00687128?
The interventions under investigation include: Low-intensity treadmill exercise (BEHAVIORAL), Moderate-intensity treadmill exercise (BEHAVIORAL), Non-aerobic stretching exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT00687128?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00687128's enrollment target sits among peer trials
93 937th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia